Terms: = Gastric cancer AND CYLD, CYLD1, 1540, ENSG00000083799, USPL2, KIAA0849, CYLDI, CDMT, HSPC057, FLJ31664, FLJ20180, EAC AND Treatment
56 results:
1. Phenotypic immune characterization of gastric and esophageal adenocarcinomas reveals profound immune suppression in esophageal tumor locations.
Groen-van Schooten TS; Harrasser M; Seidel J; Bos EN; Fleitas T; van Mourik M; Pouw RE; Goedegebuure RSA; Doeve BH; Sanders J; Bos J; van Berge Henegouwen MI; Thijssen VLJL; van Grieken NCT; van Laarhoven HWM; de Gruijl TD; Derks S
Front Immunol; 2024; 15():1372272. PubMed ID: 38638445
[TBL] [Abstract] [Full Text] [Related]
2. treatment of esophageal adenocarcinoma in patients with a history of bariatric surgery.
Nobel T; Sewell M; Boerner T; Bains MS; Bott MJ; Gerdes H; Gray K; Nishimura M; Park BJ; Shah P; Sihag S; Jones DR; Molena D
J Gastrointest Surg; 2024 Apr; 28(4):337-342. PubMed ID: 38583881
[TBL] [Abstract] [Full Text] [Related]
3. [Barrett's esophagus: Diagnosis, treatment and minimizing of risk].
Thorell A; Bednarska O; Jeremiasen M; Mottacki N; Lundell L
Lakartidningen; 2023 Sep; 120():. PubMed ID: 37746770
[TBL] [Abstract] [Full Text] [Related]
4. Reflux conditions induce E-cadherin cleavage and EMT via APE1 redox function in oesophageal adenocarcinoma.
Lu H; Cao LL; Ballout F; Belkhiri A; Peng D; Chen L; Chen Z; Soutto M; Wang TC; Que J; Giordano S; Washington MK; Chen S; McDonald OG; Zaika A; El-Rifai W
Gut; 2023 Dec; 73(1):47-62. PubMed ID: 37734913
[TBL] [Abstract] [Full Text] [Related]
5. Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced gastric/Gastroesophageal Junction cancer or Esophageal Adenocarcinoma From CheckMate 649.
Moehler M; Xiao H; Blum SI; Elimova E; Cella D; Shitara K; Ajani JA; Janjigian YY; Garrido M; Shen L; Yamaguchi K; Liu T; Schenker M; Kowalyszyn R; Bragagnoli AC; Bruges R; Montesarchio V; Pazo-Cid R; Hunter S; Davenport E; Wang J; Kondo K; Li M; Wyrwicz L
J Clin Oncol; 2023 Dec; 41(35):5388-5399. PubMed ID: 37713657
[TBL] [Abstract] [Full Text] [Related]
6. The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis.
Simon AG; Lyu SI; Laible M; Wöll S; Türeci Ö; Şahin U; Alakus H; Fahrig L; Zander T; Buettner R; Bruns CJ; Schroeder W; Gebauer F; Quaas A
J Transl Med; 2023 Aug; 21(1):552. PubMed ID: 37592303
[TBL] [Abstract] [Full Text] [Related]
7. Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.
Carroll TM; Chadwick JA; Owen RP; White MJ; Kaplinsky J; Peneva I; Frangou A; Xie PF; Chang J; Roth A; Amess B; James SA; Rei M; Fuchs HS; McCann KJ; Omiyale AO; Jacobs BA; Lord SR; Norris-Bulpitt S; Dobbie ST; Griffiths L; Ramirez KA; Ricciardi T; Macri MJ; Ryan A; Venhaus RR; Van den Eynde BJ; Karydis I; Schuster-Böckler B; Middleton MR; Lu X;
Cancer Cell; 2023 Jul; 41(7):1222-1241.e7. PubMed ID: 37433281
[TBL] [Abstract] [Full Text] [Related]
8. Long-Term Postsurgical Outcomes of Neoadjuvant Chemoradiation (CROSS) Versus Chemotherapy (FLOT) for Multimodal treatment of Adenocarcinoma of the Esophagus and the Esophagogastric Junction.
Gebauer F; Plum PS; Damanakis A; Chon SH; Popp F; Zander T; Quaas A; Fuchs H; Schmidt T; Schröder W; Bruns CJ
Ann Surg Oncol; 2023 Nov; 30(12):7422-7433. PubMed ID: 37210683
[TBL] [Abstract] [Full Text] [Related]
9. Sex differences in treatment allocation and survival of potentially curable gastroesophageal cancer: A population-based study.
Kalff MC; Dijksterhuis WPM; Wagner AD; Oertelt-Prigione S; Verhoeven RHA; Lemmens VEPP; van Laarhoven HWM; Gisbertz SS; van Berge Henegouwen MI
Eur J Cancer; 2023 Jul; 187():114-123. PubMed ID: 37146505
[TBL] [Abstract] [Full Text] [Related]
10. Quality-adjusted time without symptoms or toxicity analysis of nivolumab plus chemotherapy versus chemotherapy alone for the management of previously untreated patients with advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.
Lin D; Nguyen H; Shah R; Qiao Y; Hartman J; Sugarman R
Gastric Cancer; 2023 May; 26(3):415-424. PubMed ID: 36943511
[TBL] [Abstract] [Full Text] [Related]
11. Global retrospective analysis of clinician- and patient-reported clinical characteristics and humanistic burden of patients with gastroesophageal cancers on first-line treatment.
Xiao H; Bertwistle D; Khela K; Middleton-Dalby C; Hall J
BMC Cancer; 2023 Feb; 23(1):186. PubMed ID: 36823552
[TBL] [Abstract] [Full Text] [Related]
12. First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis.
Liu T; Bai Y; Lin X; Li W; Wang J; Zhang X; Pan H; Bai C; Bai L; Cheng Y; Zhang J; Zhong H; Ba Y; Hu W; Xu R; Guo W; Qin S; Yang N; Lu J; Shitara K; Lei M; Li M; Bao N; Chen T; Shen L
Int J Cancer; 2023 Feb; 152(4):749-760. PubMed ID: 36121651
[TBL] [Abstract] [Full Text] [Related]
13. [Clinical characteristics of 272 437 patients with different histopathological subtypes of primary esophageal malignant tumors].
Wang LD; Li X; Song XK; Zhao FY; Zhou RH; Xu ZC; Liu AL; Li JL; Li XZ; Wang LG; Zhang FH; Zhu XM; Li WX; Zhao GZ; Guo WW; Gao XM; Li LX; Wan JW; Ku QX; Xu FG; Zhu AF; Ji HX; Li YL; Ren SL; Zhou PN; Chen QD; Bao SG; Gao HJ; Yang JC; Wei WM; Mao ZZ; Han ZW; Chang YF; Zhou XN; Han WL; Han LL; Lei ZM; Fan R; Wang YZ; Yang JJ; Ji Y; Chen ZJ; Li YF; Hu L; Sun YJ; Chen GL; Bai D; You D
Zhonghua Nei Ke Za Zhi; 2022 Sep; 61(9):1023-1030. PubMed ID: 36008295
[No Abstract] [Full Text] [Related]
14. Cost-effectiveness analysis of nivolumab plus standard chemotherapy versus chemotherapy alone for the first-line treatment of unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.
Jiang Y; Li Y; Wang LXW
Int J Clin Pharm; 2022 Apr; 44(2):499-506. PubMed ID: 35088231
[TBL] [Abstract] [Full Text] [Related]
15. Proanthocyanidins mitigate bile acid-induced changes in GSTT2 levels in a panel of racially diverse patient-derived primary esophageal cell cultures.
Weh KM; Turgeon DK; Rubenstein JH; Clarke JL; Howell AB; Chang AC; Kresty LA
Mol Carcinog; 2022 Mar; 61(3):281-287. PubMed ID: 34758158
[TBL] [Abstract] [Full Text] [Related]
16. Comparison of East-Asia and West-Europe cohorts explains disparities in survival outcomes and highlights predictive biomarkers of early gastric cancer aggressiveness.
Pereira C; Park JH; Campelos S; Gullo I; Lemos C; Solorzano L; Martins D; Gonçalves G; Leitão D; Lee HJ; Kong SH; André A; Borges C; Almeida D; Wälbhy C; Almeida R; Kim WH; Carneiro F; Yang HK; Almeida GM; Oliveira C
Int J Cancer; 2022 Mar; 150(5):868-880. PubMed ID: 34751446
[TBL] [Abstract] [Full Text] [Related]
17. Exosomal microRNA-588 from M2 polarized macrophages contributes to cisplatin resistance of gastric cancer cells.
Cui HY; Rong JS; Chen J; Guo J; Zhu JQ; Ruan M; Zuo RR; Zhang SS; Qi JM; Zhang BH
World J Gastroenterol; 2021 Sep; 27(36):6079-6092. PubMed ID: 34629821
[TBL] [Abstract] [Full Text] [Related]
18. Integrated Safety Analysis of Abrocitinib for the treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program.
Simpson EL; Silverberg JI; Nosbaum A; Winthrop KL; Guttman-Yassky E; Hoffmeister KM; Egeberg A; Valdez H; Zhang M; Farooqui SA; Romero W; Thorpe AJ; Rojo R; Johnson S
Am J Clin Dermatol; 2021 Sep; 22(5):693-707. PubMed ID: 34406619
[TBL] [Abstract] [Full Text] [Related]
19. Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI cancer Audit.
Kalff MC; Wagner AD; Verhoeven RHA; Lemmens VEPP; van Laarhoven HWM; Gisbertz SS; van Berge Henegouwen MI;
Gastric Cancer; 2022 Jan; 25(1):22-32. PubMed ID: 34365540
[TBL] [Abstract] [Full Text] [Related]
20. [Influence of molecular pathology on oncological surgery of tumors of the upper gastrointestinal tract].
Plum PS; Quaas A; Alakus H; Bruns CJ
Chirurg; 2021 Nov; 92(11):981-985. PubMed ID: 34287671
[TBL] [Abstract] [Full Text] [Related]
[Next]
